Introduction {#s0005}
============

In the United States, screening for cervical cancer is a standard component of women\'s routine preventive healthcare, and has dramatically reduced cervical cancer incidence and mortality over the last six decades ([@bb0005]). Current guidelines recommend screening intervals of 3 to 5 years following normal test results, based on the screening test used. Despite successful integration of cervical cancer screening into women\'s routine care, some uninsured and low-income women are screened less often than recommended and suffer disproportionate cervical cancer morbidity, mortality, and late-stage diagnosis ([@bb0010], [@bb0015], [@bb0020]). Conversely, too-frequent cervical cancer screening has also been documented in both the medically underserved and general population ([@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055]). Plausible explanations include opportunistic clinical service provision ([@bb0005]), provider specialty ([@bb0025], [@bb0055]), practice setting ([@bb0055]) and size ([@bb0035]), provider concern for losing the patient to follow-up ([@bb0030], [@bb0035], [@bb0050]), patient expectations ([@bb0030], [@bb0035], [@bb0045], [@bb0050]), and provider knowledge ([@bb0045]).

In 2009, the Centers for Disease Control and Prevention (CDC) launched the Cervical Cancer (Cx3) Study to examine both provider and patient knowledge, attitudes, and beliefs about co-testing (i.e., simultaneous Pap and human papillomavirus testing) and extended screening intervals in a medically underserved population ([@bb0060], [@bb0065], [@bb0070]). Baseline survey data collected for the study found that many providers recommended annual screening for women after a normal co-test despite guidelines at the time recommending a triennial interval. Providers also reported that extending the screening interval to three years with a normal co-test would result in the patent not returning annually for others tests and losing contact with the medical system ([@bb0070]). The purpose of the current analysis was to examine what provider characteristics and beliefs were associated with their screening interval recommendations (annual versus triennial interval) using the baseline survey data.

Method {#s0010}
======

The Cx3 Study was a pilot study conducted in 15 clinics associated with six Federally Qualified Health Centers (FQHCs) in Illinois, USA. In the United States, FQHCs are funded by the U.S. Department of Health and Human Services\' Health Resources and Services Administration (HRSA) under Section 330 of the U.S. Public Health Service Act. FQHCs are safety-net clinics, and are mandated to serve an underserved area or population, offer a sliding fee scale, and provide preventive primary care services serve almost 22 million patients annually.

In recent years, HRSA-supported FQHCs have received funding to expand operations and provide clinical services to a greater number of medically underserved patients (<http://bphc.hrsa.gov/about/healthcenterfactsheet.pdf>). Providers working in FQHCs may face challenges related to increased patient load, and therefore FQHCs may experience higher staff turnover. Incentives to improve recruitment and retention of clinicians in underserved areas are being employed ([@bb0075]).

All providers (physicians, nurse practitioners, certified nurse midwives, and physician assistants) in the participating clinics who routinely performed cervical cancer screening were eligible to participate (n = 109). Between 2009 and 2010, we sent self-administered, cross-sectional surveys and a \$50 cash incentive to eligible providers with a stamped, self-addressed envelope for return; 98 providers completed the survey (89.9% response rate).

The survey collected provider demographic characteristics, practice characteristics, and screening practices and beliefs. A clinical vignette asked the provider when they would next screen a woman aged 35 years with a normal co-test result. Response options were 1 year, 2 years, 3 years, \> 3 years. For this analysis, we used responses from the clinical vignette to compare the characteristics and beliefs of providers who recommended a 1-year interval (n = 57) to those of providers who recommended a 3-year interval (n = 25) (guideline-consistent at the time of the survey) as a method for defining guideline compliance and non-compliance. Significance of associations between these two interval recommendations were tested with Pearson chi-square, negative binomial and ordered logistic regression. All methods adjusted for the clustered sampling design. Missing data was handled with listwise deletion. CDC\'s Institutional Review Board approved the study. Additional details on study methods are published elsewhere [@bb0060], [@bb0070].

Results {#s0015}
=======

Providers were primarily female (74%), physicians (67%) or nurse practitioners (21%), trained in OB/GYN (56%) or family medicine (35%), with an average of 8.9 years of providing clinical care (n = 82). Gender, specialty, provider type, and years in practice were not found to be significantly associated with screening interval recommendation ([Table 1](#t0005){ref-type="table"}).

Providers were asked their beliefs about extending screening intervals for a woman aged ≥ 30 years with a normal co-test result. Providers who recommended a 3-year interval after a normal co-test were *more likely* to report that extending routine screening to 3 years would be good (80%), easy (67%) and beneficial (68%) compared to providers who recommended annual screening after a normal co-test (p \< .05) ([Fig. 1](#f0005){ref-type="fig"}).

Providers were asked to report level of agreement with common concerns about extending the screening interval after a normal co-test, including the patient not visiting annually for other screening tests, increased risk for the patient developing cervical cancer, higher rates of pre-cancer, or the patient losing contact with the medical system. Providers who recommended a 3-year interval were significantly *more likely* to disagree that an extended interval would put the patient at increased risk for cancer (56%) (p \< .05) and would result in higher rates of pre-cancer (68%) (p = .055) ([Table 2](#t0010){ref-type="table"}).

Providers were asked about their perceived support for extending the screening interval after a normal co-test from patients, clinic administration, colleagues, professional specialty organizations, national health organizations, and professional journals. Providers who recommended a 3-year interval were significantly *more likely* to perceive support for that practice from professional specialty organizations and journals (80%) (p \< .05) and national health organizations (76%) (p = .051) ([Table 2](#t0010){ref-type="table"}).

Discussion {#s0020}
==========

Despite guidelines recommending longer intervals between cervical cancer screenings, women continue to be screened annually. These data identify specific beliefs associated with providers guideline-consistent screening interval recommendations, including beliefs about the goodness, ease, and benefit of extending screening intervals with a normal co-test result, and that extending the interval will not put the patient at increased risk of developing cancer or pre-cancer. Disseminating the positive beliefs found to be associated with 3-year intervals through professional specialty organizations and professional journals could be effective for promoting guideline-consistent interval recommendations among this population, as was found in a survey of Indiana primary care providers [@bb0030]. Notably, nonmodifiable provider characteristics such as specialty, age, and gender were not associated with interval recommendations in this analysis.

Additional methods found to be effective for changing provider\'s cervical cancer screening knowledge, behaviors and attitudes include electronic medical record-based tools ([@bb0080]) provider assessment and feedback, [@bb0085] and academic detailing ([@bb0090]), patient driven inquiry, and management guidelines ([@bb0030]). Interventions and messages about cervical cancer screening should prevent the harms and risks of routine screening, in addition to the benefits. CDC has produced materials to educate providers and patients on the appropriate use of the co-test that may be adapted to reflect the needs of the target population and the latest science ([@bb0060]).

To date, no studies have examined provider and patient acceptance of co-testing with longer screening intervals in a medically underserved population, and therefore these are novel data. Collecting information on beliefs associated with FQHC provider screening interval recommendations is essential because as the science evolves, so will screening guidelines and screening modalities, and targeting provider beliefs and attitudes will be critical to promote uptake of new evidence-based recommendations. Results from this study will assist CDC in providing technical assistance to cancer screening programs regarding use of the co-test. Because of the small convenience sample, these findings may not be generalizable to other FQHCs or providers in Illinois. Other limitations include the data were self-reported, incentives were provided to complete the survey, and additional details on provider training and demographics are unknown.

Conclusion {#s0025}
==========

Cervical cancer screening in the United States can be improved by reducing the frequency of screening intervals for over-screened women to be consistent with guidelines, and directing realized savings toward increasing screening among rarely or never-screened women ([@bb0095]). We found that screening interval recommendations were dictated not by provider demographics but by positive beliefs regarding longer screening intervals. While this is not surprising, these findings do indicate avenues for dissemination of such beliefs that could be promoted and disseminated to counter views about the risks of longer screening intervals. Future research regarding how to communicate relative risk and harms of over-screening is critical. Provider\'s perceived risks such as being held accountable for a missed diagnosis ([@bb0070]), as well as losing the patient to follow-up ([@bb0070]) and her risk of developing cancer are genuine. The lack of widespread and equitable screening participation, particularly among under- and over-screened women, is a call to action for public health programs ([@bb0100]). Reducing unnecessary clinical intervention is essential when community-based primary care settings with finite resources, such as FQHCs, are expected to provide optimal preventive care services to an underserved patient population.
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![Beliefs about extending cervical cancer screening intervals to 3 years after a normal co-test,^a^ according to screening interval recommendations, among 82 providers at Federally Qualified Health Centers, Illinois, 2009--2010.\
Significance of associations between these two interval recommendations and beliefs were tested with ordered logistic regression and adjusted for clustered sampling design.\
^a^ Co-test (i.e., simultaneous Pap and human papillomavirus test).](gr1){#f0005}

###### 

Demographic characteristics of study providers according to screening interval recommendations with the co-test [a](#tf0015){ref-type="table-fn"} among 82 providers at Federally Qualified Health Centers, Illinois, 2009--2010.

                                                Sample description   Recommended screening interval for patient aged 35 years with normal co-test this visit                                        
  --------------------------------------------- -------------------- ----------------------------------------------------------------------------------------- ----------- ------- ----- ----- ---- -------
  Primary specialty                             Family medicine      35%                                                                                       29          76%     22    24%   7    0.382
  OB--GYN/women\'s health                       56%                  46                                                                                        63%         29      37%   17         
  Other                                         9%                   7                                                                                         86%         6       14%   1          
  Total                                         100%                 82                                                                                        70%         57      30%   25         
  Type of provider                              Physician            67%                                                                                       55          71%     39    29%   16   0.442
  NP                                            21%                  17                                                                                        59%         10      41%   7          
  Other                                         12%                  10                                                                                        80%         8       20%   2          
  Total                                         100%                 82                                                                                        70%         57      30%   25         
  Provider is OB/GYN physician                  Other                55%                                                                                       45          73%     33    27%   12   0.179
  OB/GYN MD                                     45%                  37                                                                                        65%         24      35%   13         
  Total                                         100%                 82                                                                                        70%         57      30%   25         
  Gender                                        Male                 26%                                                                                       21          71%     15    29%   6    0.822
  Female                                        74%                  61                                                                                        69%         42      31%   19         
  Total                                         100%                 82                                                                                        70%         57      30%   25         
  Years providing care (mean, sd)               8.9 (9.9)            9.33 (10.5)                                                                               7.8 (8.5)   0.513                    
  Years providing clinical care, 4 categories   1--4                 46%                                                                                       38          68%     26    32%   12   0.836
  5--9                                          22%                  18                                                                                        61%         11      39%   7          
  10--15                                        12%                  10                                                                                        80%         8       20%   2          
  16 +                                          20%                  16                                                                                        75%         12      25%   4          
  Total                                         100%                 82                                                                                        70%         57      30%   25         

Significance of associations with categorical variables was tested with design-adjusted Pearson chi-square.

Significance of the association with the count variable, number of years providing care, was tested with negative binomial regression.

All tests adjusted for the clustered sampling design.

Co-test (simultaneous Pap and human papillomavirus test).

###### 

Level of agreement with statements about extending the cervical cancer screening interval to 3 years after a normal co-test[a](#tf0005){ref-type="table-fn"}, according to screening interval recommendations, among 82 providers at Federally Qualified Health Centers, Illinois, 2009--2010.

                                                                                                                                                                          Recommend 1-year interval (%) (n = 57)   Recommend 3-year interval (%) (n = 25)   p-Value   
  ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------- ---------------------------------------- --------- -------
  Extending the screening interval would...                                                 Result in patient not visiting annually for other screening tests (reverse)   Agree                                    75                                       80        0.555
  Neither                                                                                   7                                                                             12                                                                                          
  Disagree                                                                                  18                                                                            8                                                                                           
  Put patient at increased risk for cervical cancer                                         Agree                                                                         40                                       12                                       0.036     
  Neither                                                                                   23                                                                            32                                                                                          
  Disagree                                                                                  37                                                                            56                                                                                          
  Result in higher rates of cervical pre-cancer                                             Agree                                                                         35                                       20                                       0.055     
  Neither                                                                                   23                                                                            12                                                                                          
  Disagree                                                                                  42                                                                            68                                                                                          
  Cause patients to lose contact with medical care system                                   Agree                                                                         68                                       48                                       0.088     
  Neither                                                                                   9                                                                             24                                                                                          
  Disagree                                                                                  23                                                                            28                                                                                          
  Do the following entities encourage or discourage you to extend the screening interval?   Patients                                                                      Discourage                               18                                       40        0.105
  Neither                                                                                   67                                                                            48                                                                                          
  Encourage                                                                                 16                                                                            12                                                                                          
  Colleagues                                                                                Discourage                                                                    28                                       16                                       0.165     
  Neither                                                                                   47                                                                            40                                                                                          
  Encourage                                                                                 25                                                                            44                                                                                          
  Clinic administration                                                                     Discourage                                                                    21                                       20                                       0.126     
  Neither                                                                                   65                                                                            56                                                                                          
  Encourage                                                                                 14                                                                            24                                                                                          
  Professional journals                                                                     Discourage                                                                    16                                       0                                        0.000     
  Neither                                                                                   36                                                                            20                                                                                          
  Encourage                                                                                 47                                                                            80                                                                                          
  Professional specialty organizations                                                      Discourage                                                                    20                                       0                                        0.000     
  Neither                                                                                   36                                                                            20                                                                                          
  Encourage                                                                                 45                                                                            80                                                                                          
  National health organizations                                                             Discourage                                                                    16                                       0                                        0.051     
  Neither                                                                                   31                                                                            24                                                                                          
  Encourage                                                                                 53                                                                            76                                                                                          

Significance of associations between these two interval recommendations and beliefs was tested with ordered logistic regression and adjusted for clustered sampling design. No missing data.

Co-test (simultaneous Pap and human papillomavirus test).
